Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVNRY Bavarian Nordic	$12.41 +0.3%	$10.20	$6.60 ▼ $14.11	$2.94B	1.36	7,925 shs	4,145 shs
MIRM Mirum Pharmaceuticals	$66.68 -1.8%	$52.89	$36.86 ▼ $69.27	$3.35B	0.94	499,618 shs	699,423 shs
PHGUF Pharming Group	$1.16	$1.15	$0.75 ▼ $1.19	$778.44M	0.65	300 shs	N/A
SRRK Scholar Rock	$31.52 +0.4%	$35.73	$6.76 ▼ $46.98	$3.03B	0.48	1.23 million shs	2.30 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVNRY Bavarian Nordic	0.00%	+0.24%	+30.07%	+46.22%	-11.33%
MIRM Mirum Pharmaceuticals	0.00%	+13.27%	+30.81%	+51.33%	+66.90%
PHGUF Pharming Group	0.00%	+1.75%	+0.87%	+21.21%	+40.62%
SRRK Scholar Rock	0.00%	-1.69%	-22.86%	+4.14%	+237.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	4.1193 of 5 stars	3.6	0.0	0.0	4.2	3.9	2.5	0.6
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	4.4844 of 5 stars	4.6	0.0	0.0	4.4	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	3.13	Buy	$74.13	11.17% Upside
PHGUF Pharming Group	0.00	N/A	N/A	N/A
SRRK Scholar Rock	3.22	Buy	$45.14	43.22% Upside

Current Analyst Ratings Breakdown

Latest PHGUF, SRRK, MIRM, and BVNRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$89.00
8/8/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $89.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
8/7/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$79.00 ➝ $81.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$77.00 ➝ $82.00
8/7/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $80.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVNRY Bavarian Nordic	$829.12M	3.54	$1.02 per share	12.22	$6.99 per share	1.78
MIRM Mirum Pharmaceuticals	$336.89M	9.94	N/A	N/A	$4.70 per share	14.19
PHGUF Pharming Group	$297.20M	2.62	N/A	N/A	$0.33 per share	3.52
SRRK Scholar Rock	$33.19M	91.29	N/A	N/A	$3.94 per share	8.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVNRY Bavarian Nordic	$143.26M	$0.80	15.51	11.82	N/A	21.11%	11.89%	9.32%	8/28/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.21	N/A	N/A	N/A	-13.65%	-24.76%	-8.50%	N/A
PHGUF Pharming Group	-$11.84M	N/A	0.00	∞	N/A	-2.19%	-3.38%	-1.82%	11/6/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	N/A

Latest PHGUF, SRRK, MIRM, and BVNRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	-$0.12	+$0.19	-$0.12	$107.91 million	$127.79 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVNRY Bavarian Nordic	N/A	2.81	1.44
MIRM Mirum Pharmaceuticals	1.21	3.13	2.97
PHGUF Pharming Group	0.51	2.76	2.00
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVNRY Bavarian Nordic	N/A
MIRM Mirum Pharmaceuticals	N/A
PHGUF Pharming Group	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
BVNRY Bavarian Nordic	N/A
MIRM Mirum Pharmaceuticals	22.87%
PHGUF Pharming Group	N/A
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
MIRM Mirum Pharmaceuticals	140	50.24 million	38.75 million	Optionable
PHGUF Pharming Group	382	671.07 million	N/A	Not Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

PHGUF, SRRK, MIRM, and BVNRY Headlines

Recent News About These Companies

Lord Abbett & CO. LLC Boosts Holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 17 at 5:49 AM | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15 at 4:15 PM | businesswire.com

Scholar Rock publishes SAPPHIRE trial data in The Lancet

August 15 at 2:42 AM | msn.com

Scholar Rock Holding: Upcoming Milestone Approaches

August 13, 2025 | seekingalpha.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by Informed Momentum Co LLC

August 13, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $45.14 Average PT from Brokerages

August 13, 2025 | americanbankingnews.com

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12, 2025 | msn.com

Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock

August 12, 2025 | americanbankingnews.com

Wedbush Issues Negative Forecast for Scholar Rock Earnings

August 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11, 2025 | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Scholar Rock (NASDAQ:SRRK) Stock Price Down 10.2% Following Weak Earnings

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $45.00 at BMO Capital Markets

August 8, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Trading Down 10.2% on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Shares Gap Down After Earnings Miss

August 7, 2025 | marketbeat.com

Scholar Rock outlines Q3 2025 U.S. apitegromab launch plans amid regulatory progress and global expansion focus

August 7, 2025 | msn.com

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGUF, SRRK, MIRM, and BVNRY Company Descriptions

Bavarian Nordic OTCMKTS:BVNRY

$12.41 +0.04 (+0.32%)

As of 03:54 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Mirum Pharmaceuticals NASDAQ:MIRM

$66.68 -1.25 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$66.67 -0.01 (-0.01%)

As of 04:10 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Pharming Group OTCMKTS:PHGUF

$1.16 0.00 (0.00%)

As of 08/15/2025

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Scholar Rock NASDAQ:SRRK

$31.52 +0.11 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$31.80 +0.28 (+0.89%)

As of 04:12 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time